https://www.selleckchem.com/pr....oducts/cordycepin.ht
MC mediator-related symptoms were evaluated using a specific physician-reported questionnaire. Results Over the first 6 cycles of treatment with midostaurin (ie, 6 months), patients experienced significant improvements in total SF-12 and MSAS scores, as well as in subscores of each instrument. These improvements were durable during 36 months of follow-up. Similarly, we found substantial improvements (67%-100%) in all MC mediator-related symptoms. Conclusion QOL and MC mediator-related symptoms significantly improve with midostaurin t
Like
Comment
Share
